<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="VirusesVirusesvirusesViruses1999-4915MDPI pmcid: 7472103 doi: 10.3390/v12080862viruses-12-00862 : Review Emerging Role of" exact="Mucosal" post="Vaccine in Preventing Infection with Avian Influenza A Viruses"/>
 <result pre="10.3390/v12080862viruses-12-00862 : Review Emerging Role of Mucosal Vaccine in Preventing" exact="Infection" post="with Avian Influenza A Viruses WangTong1https://orcid.org/0000-0002-2997-922XWeiFanhua2LiuJinhua1*[1], wtong0819@163.com[2], weifanhua999@163.com *Correspondence:"/>
 <result pre="Review Emerging Role of Mucosal Vaccine in Preventing Infection with" exact="Avian" post="Influenza A Viruses WangTong1https://orcid.org/0000-0002-2997-922XWeiFanhua2LiuJinhua1*[1], wtong0819@163.com[2], weifanhua999@163.com *Correspondence: ljh@cau.edu.cn epub:"/>
 <result pre="of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract" exact="Avian" post="influenza A viruses (AIVs), as a zoonotic agent, dramatically"/>
 <result pre="impacts public health and the poultry industry. Although low pathogenic" exact="avian influenza" post="virus (LPAIV) incidence and mortality are relatively low, the"/>
 <result pre="of safe and efficacious mucosal vaccines that mimic the natural" exact="infection" post="route and cut off the AIVs infection route. Here,"/>
 <result pre="mimic the natural infection route and cut off the AIVs" exact="infection" post="route. Here, we discussed the current status and advancement"/>
 <result pre="review will help to not only understand and predict AIVs" exact="infection" post="characteristics in birds but also extrapolate them for distinction"/>
 <result pre="distinction or applicability in mammals, including humans. influenza virus poultry" exact="upper" post="respiratory tract mucosal immunity mucosal vaccines 1. Introduction Avian"/>
 <result pre="or applicability in mammals, including humans. influenza virus poultry upper" exact="respiratory" post="tract mucosal immunity mucosal vaccines 1. Introduction Avian influenza"/>
 <result pre="poultry upper respiratory tract mucosal immunity mucosal vaccines 1. Introduction" exact="Avian" post="influenza A viruses (AIVs) remain one of the important"/>
 <result pre="Avian influenza A viruses (AIVs) remain one of the important" exact="viral" post="pathogens that cause respiratory tract infections in various animal"/>
 <result pre="(AIVs) remain one of the important viral pathogens that cause" exact="respiratory" post="tract infections in various animal species, such as poultry"/>
 <result pre="one of the important viral pathogens that cause respiratory tract" exact="infections" post="in various animal species, such as poultry and humans,"/>
 <result pre="cleavage site in the HA protein as well as the" exact="disease" post="severity in poultry. Infection with low pathogenic avian influenza"/>
 <result pre="HA protein as well as the disease severity in poultry." exact="Infection" post="with low pathogenic avian influenza virus (LPAIV) results in"/>
 <result pre="as the disease severity in poultry. Infection with low pathogenic" exact="avian influenza" post="virus (LPAIV) results in mild respiratory disorder accompanied with"/>
 <result pre="with low pathogenic avian influenza virus (LPAIV) results in mild" exact="respiratory" post="disorder accompanied with reduced egg production and/or a depression,"/>
 <result pre="disorder accompanied with reduced egg production and/or a depression, whereas" exact="infections" post="with highly pathogenic avian influenza virus (HPAIV) cause a"/>
 <result pre="egg production and/or a depression, whereas infections with highly pathogenic" exact="avian influenza" post="virus (HPAIV) cause a significant mortality in chickens. Notably,"/>
 <result pre="evoke a better local immune response [17]. Given that the" exact="infection" post="and spread of AIVs occur at mucosal surfaces, vaccine"/>
 <result pre="mucosal route could provide the first line of defense against" exact="viral" post="infections through inducing mucosal immunity. Moreover, mucosal vaccines are"/>
 <result pre="route could provide the first line of defense against viral" exact="infections" post="through inducing mucosal immunity. Moreover, mucosal vaccines are designed"/>
 <result pre="and to trigger â€œfrontline immunityâ€� for IgA production in the" exact="upper" post="respiratory tract (URT), controlling viral infection. Therefore, understanding the"/>
 <result pre="to trigger â€œfrontline immunityâ€� for IgA production in the upper" exact="respiratory" post="tract (URT), controlling viral infection. Therefore, understanding the underlying"/>
 <result pre="for IgA production in the upper respiratory tract (URT), controlling" exact="viral infection." post="Therefore, understanding the underlying mechanisms for mucosal immunity would"/>
 <result pre="adopt more adequate vaccine strategies for the control of AIVs" exact="infection" post="and epidemics. 2. Host Immune Responses to Influenza Viruses"/>
 <result pre="constitutes the first line of protection from invading pathogens. AIV" exact="infection" post="results in a recognition of viral conserved components called"/>
 <result pre="from invading pathogens. AIV infection results in a recognition of" exact="viral" post="conserved components called pathogen associated molecular patterns (PAMPs) by"/>
 <result pre="(TLR15), and double stranded DNA (dsDNA) (TLR21) [21]. For influenza" exact="virus infection," post="endosomal TLR3 and TLR7 recognize viral infection-produced dsRNA and"/>
 <result pre="[21]. For influenza virus infection, endosomal TLR3 and TLR7 recognize" exact="viral" post="infection-produced dsRNA and ssRNA genome, respectively (Figure 1). TLR3"/>
 <result pre="infection-produced dsRNA and ssRNA genome, respectively (Figure 1). TLR3 is" exact="localized" post="on the surface of bronchial and alveolar epithelial cells"/>
 <result pre="TLR3 is localized on the surface of bronchial and alveolar" exact="epithelial" post="cells as well as to their endosomes. TLR3 pathway"/>
 <result pre="and interferon regulatory factor 3 (IRF3), inducing the expression of" exact="type I" post="interferons (IFNs) and proinflammatory cytokines. TLR7 is a receptor"/>
 <result pre="(IFNs) and proinflammatory cytokines. TLR7 is a receptor for influenza" exact="viral" post="ssRNA in endolysosomal compartments of plasmacytoid dendritic cells (pDCs)."/>
 <result pre="TLR ligands promising candidates for vaccine adjuvants. The RLRsâ€&quot;RIG-I and" exact="melanoma" post="differentiation-associated protein 5 (MDA5)â€&quot;recognize the cytoplasmic viral non-self RNA"/>
 <result pre="The RLRsâ€&quot;RIG-I and melanoma differentiation-associated protein 5 (MDA5)â€&quot;recognize the cytoplasmic" exact="viral" post="non-self RNA and transcripts. RIG-I preferentially binds cytoplasmic single-strand"/>
 <result pre="MDA5 is activated by long dsRNA species [23]. Upon influenza" exact="virus infection," post="the repressor domain (RD) of RIG-I recognizes the viral"/>
 <result pre="virus infection, the repressor domain (RD) of RIG-I recognizes the" exact="viral" post="RNA molecule, resulting in the release of RD-mediated autoinhibition"/>
 <result pre="that ultimately activates transcription factors such as IRF3 to induce" exact="type I" post="IFNs expression [26,27]. Although RIG-I is absent in chickens,"/>
 <result pre="IFNs expression [26,27]. Although RIG-I is absent in chickens, the" exact="absence of" post="chick RIG-I can be functionally compensated by MDA5. In"/>
 <result pre="that in mammals [28]. The roles of NLR signaling in" exact="bacterial infection" post="have been broadly investigated [29]. IAV infection activates NLR"/>
 <result pre="in mammals [28]. The roles of NLR signaling in bacterial" exact="infection" post="have been broadly investigated [29]. IAV infection activates NLR"/>
 <result pre="signaling in bacterial infection have been broadly investigated [29]. IAV" exact="infection" post="activates NLR family pyrin domain containing 3 (NLRP3) and"/>
 <result pre="3 (NLRP3) and NLR apoptosis inhibitory protein 5 [30]. Notably," exact="viral" post="PB1-F2 protein acts as the signal activating the NLRP3"/>
 <result pre="signaling is involved in the protective adaptive responses to IAV" exact="infection" post="[33]. Conversely, other studies demonstrated that the NLRP3 signaling"/>
 <result pre="adaptive immune response comprising humoral and cellular responses at both" exact="systemic" post="and mucosal levels constitutes the second line of defense"/>
 <result pre="[36]. In the case of the humoral immune response, influenza" exact="virus infection" post="leads to production of antibodies (Abs) against the viral"/>
 <result pre="In the case of the humoral immune response, influenza virus" exact="infection" post="leads to production of antibodies (Abs) against the viral"/>
 <result pre="virus infection leads to production of antibodies (Abs) against the" exact="viral" post="surface glycoproteins, particularly HA. Abs raised against the globular"/>
 <result pre="endocytosis mediated by the receptors. As most Abs recognizing the" exact="viral" post="HA exhibit virus strain-specific activities, they are ineffective in"/>
 <result pre="to the presence of sialydase activities. NA Abs inhibit the" exact="viral" post="spread and decrease the disease severity through suppressing the"/>
 <result pre="activities. NA Abs inhibit the viral spread and decrease the" exact="disease" post="severity through suppressing the enzymatic activities [38]. It should"/>
 <result pre="NP-specific Abs stimulate the activity of natural killer cells [40]." exact="Infection" post="with influenza viruses initiates virus-specific cellular immune response involving"/>
 <result pre="cell subsets in response to distinct stimulatory factors produced by" exact="epithelial" post="cells, DCs, and inflammatory cells [43]. Th1 cells secret"/>
 <result pre="Memory CD4+ T cells play a role in controlling the" exact="secondary" post="influenza infection that is independent of CD8+ T cells"/>
 <result pre="T cells play a role in controlling the secondary influenza" exact="infection" post="that is independent of CD8+ T cells or B"/>
 <result pre="vital subset of immune cells, are activated after recognition of" exact="viral" post="epitopes on DCs that migrate from the lung tissue"/>
 <result pre="CTLs can also be induced by proinflammatory cytokines, including IFN-Î³," exact="type I" post="IFNs, IL-2, and IL-12 [52]. CTLs have the capacity"/>
 <result pre="GrA prevents virus replication and exerts non-cytotoxic effects through cleaving" exact="viral" post="and host cell proteins related to protein synthesis [55]."/>
 <result pre="are mainly directed against epitopes of the highly conserved internal" exact="viral" post="proteins, like M1, NP, polymerase acid (PA), and polymerase"/>
 <result pre="and display cross-reactivities among various subtypes of IAVs [57]. 2.3." exact="Mucosal" post="Immune Response to Influenza Virus The mucosal immune system"/>
 <result pre="The mucosal immune system plays a crucial role in controlling" exact="infection" post="with influenza viruses in the URT (Figure 2). The"/>
 <result pre="immune system in the host responds to the initial IAV" exact="infection" post="by producing antiviral and immunomodulatory components, including mucins, lectins,"/>
 <result pre="molecules, and natural immunoglobulins [58]. The entry of IAVs into" exact="epithelial" post="cells renders detection of the viral PAMPs by the"/>
 <result pre="entry of IAVs into epithelial cells renders detection of the" exact="viral" post="PAMPs by the local immune cells via PRRs. The"/>
 <result pre="In the mucosa, IgG plays a major role in decreasing" exact="viral pneumonia" post="rather than preventing the upper respiratory system infections [59]."/>
 <result pre="the mucosa, IgG plays a major role in decreasing viral" exact="pneumonia" post="rather than preventing the upper respiratory system infections [59]."/>
 <result pre="major role in decreasing viral pneumonia rather than preventing the" exact="upper" post="respiratory system infections [59]. In contrast to IgG, IgA"/>
 <result pre="role in decreasing viral pneumonia rather than preventing the upper" exact="respiratory" post="system infections [59]. In contrast to IgG, IgA exerts"/>
 <result pre="decreasing viral pneumonia rather than preventing the upper respiratory system" exact="infections" post="[59]. In contrast to IgG, IgA exerts a key"/>
 <result pre="to IgG, IgA exerts a key role in preventing from" exact="infection" post="of the human URT mucosa with influenza viruses [60],"/>
 <result pre="key role in preventing from infection of the human URT" exact="mucosa" post="with influenza viruses [60], eliminating viruses from the infected"/>
 <result pre="neutralized by secretory IgA (S-IgA) on the surface of the" exact="respiratory" post="mucosa prior to their attachment to epithelium and penetration"/>
 <result pre="by secretory IgA (S-IgA) on the surface of the respiratory" exact="mucosa" post="prior to their attachment to epithelium and penetration into"/>
 <result pre="prior to their attachment to epithelium and penetration into the" exact="epithelial" post="surface (Figure 2). In addition, influenza-virus-induced S-IgA in the"/>
 <result pre="epithelial surface (Figure 2). In addition, influenza-virus-induced S-IgA in the" exact="respiratory" post="mucosa is more potent than serum IgG for cross-reactivity"/>
 <result pre="surface (Figure 2). In addition, influenza-virus-induced S-IgA in the respiratory" exact="mucosa" post="is more potent than serum IgG for cross-reactivity against"/>
 <result pre="A/Yamagata/120/86) HA immunization can lead to protection of mice against" exact="infection" post="with multiple virus strains [62,63]. In this case, while"/>
 <result pre="in a decline in the efficiency of protection against heterologous" exact="virus infection" post="[64]. It has been demonstrated that S-IgA purified from"/>
 <result pre="a decline in the efficiency of protection against heterologous virus" exact="infection" post="[64]. It has been demonstrated that S-IgA purified from"/>
 <result pre="B cells to IgA-producing cells [68]. 3. The Importance of" exact="Mucosal" post="Immunity against Influenza Virus Infection At present, the commercial"/>
 <result pre="[68]. 3. The Importance of Mucosal Immunity against Influenza Virus" exact="Infection" post="At present, the commercial vaccines against influenza available on"/>
 <result pre="formaldehyde or Î²-propiolactone, concentration, and purification. WIV has safe and" exact="complete" post="antigenic components that are nontoxic and have strong immunogenicity"/>
 <result pre="treatments with diethyl ether or detergents for exposure of all" exact="viral" post="proteins [72]. The subunit vaccines are prepared by extracting"/>
 <result pre="of sufficient immunity. The RIV vaccines are generated through a" exact="viral" post="host (baculovirus Autographa californica nuclear polyhedrosis virus) in the"/>
 <result pre="or intramuscularly, can elevate the level of serum Abs at" exact="systemic" post="immune compartments, providing the most efficient, valuable, and low-cost"/>
 <result pre="most efficient, valuable, and low-cost means for effectively controlling the" exact="virus infection" post="and subsequently reducing morbidity and mortality. However, all these"/>
 <result pre="efficient, valuable, and low-cost means for effectively controlling the virus" exact="infection" post="and subsequently reducing morbidity and mortality. However, all these"/>
 <result pre="to elicit local mucosal immunity on the location of initial" exact="infection" post="[73], representing a limited capacity of the conventional vaccines"/>
 <result pre="immunity on the location of initial infection [73], representing a" exact="limited" post="capacity of the conventional vaccines in conferring broad protective"/>
 <result pre="strains, the effectiveness of these vaccines becomes very low. The" exact="respiratory" post="mucosa is the first target of influenza virus, constituting"/>
 <result pre="the effectiveness of these vaccines becomes very low. The respiratory" exact="mucosa" post="is the first target of influenza virus, constituting the"/>
 <result pre="infection, which can effectively prevent the virus from entering [74]." exact="Mucosal" post="vaccines are designed to mimic the natural process of"/>
 <result pre="vaccines are designed to mimic the natural process of virus" exact="infections" post="and evoke better mucosal immune responses than parenteral vaccines."/>
 <result pre="on the mucosal surface have the capacity to effectively prevent" exact="virus infection" post="due to the fact that these Abs remain active"/>
 <result pre="the mucosal surface have the capacity to effectively prevent virus" exact="infection" post="due to the fact that these Abs remain active"/>
 <result pre="prior to attachment of the pathogens to mucosal epithelium, the" exact="primary" post="site for virus infection. Furthermore, S-IgA Abs display more"/>
 <result pre="of the pathogens to mucosal epithelium, the primary site for" exact="virus infection." post="Furthermore, S-IgA Abs display more effective protection against the"/>
 <result pre="been shown that mucosal vaccines induce cross-reacting Ab in the" exact="respiratory" post="tract, providing cross-protection against heterologous virus infection. Inoculating the"/>
 <result pre="cross-reacting Ab in the respiratory tract, providing cross-protection against heterologous" exact="virus infection." post="Inoculating the influenza HA vaccine together with cholera toxin"/>
 <result pre="heterologous virus infection. Inoculating the influenza HA vaccine together with" exact="cholera" post="toxin B subunit (CTB) or B subunit of heat-labile"/>
 <result pre="(CTB) or B subunit of heat-labile enterotoxin (LTB) supplemented with" exact="cholera" post="toxin (CT) intranasally enhanced anti-HA lgA and IgG Ab"/>
 <result pre="in nasal wash or serum, which protect mice against variant" exact="virus infection" post="[77]. Okamoto et al. found that intranasal formalin-inactivated whole-virion"/>
 <result pre="nasal wash or serum, which protect mice against variant virus" exact="infection" post="[77]. Okamoto et al. found that intranasal formalin-inactivated whole-virion"/>
 <result pre="the viruses and identify the molecular pathogenesis related to influenza" exact="infection" post="and the working mechanism underlying normal mucosal immunization. 4."/>
 <result pre="the working mechanism underlying normal mucosal immunization. 4. Strategies for" exact="Mucosal" post="Vaccination Researchers have been attempting to create universal influenza"/>
 <result pre="viruses. In recent years, research on the prevention of influenza" exact="infection" post="by nasal immunity has gained more and more attention."/>
 <result pre="mucosal vaccines must be designed to possess the characteristics of" exact="mucosa" post="and promote the specific immune responses to vaccine antigens"/>
 <result pre="rather than at 37 Â°C, deterring their replication in the" exact="lower" post="airway, including lung tissue, and the subsequent occurrence of"/>
 <result pre="airway, including lung tissue, and the subsequent occurrence of influenza-like" exact="disease" post="[80]. The most important feature of LAIVs is that"/>
 <result pre="important feature of LAIVs is that they elicit a minor" exact="infection" post="at the site of challenge and present a high"/>
 <result pre="exposure [81]. Ideally, LAIVs have been constructed to possess a" exact="limited" post="replication capacity to avoid undesirable inflammatory response while delivering"/>
 <result pre="are developed for the control of influenza, rotavirus, norovirus and" exact="measles" post="viruses [83]. Experimental LAIVs have been found to be"/>
 <result pre="a high immunogenicity. In the other case, the live oral" exact="typhoid" post="vaccine exhibits moderate immunogenicity but good safety due to"/>
 <result pre="that can be highly desirable to generate a safe and" exact="stable" post="live vaccine. Further studies on the genetic basis of"/>
 <result pre="improvements in the safety and stability of the vaccines. 4.2." exact="Mucosal" post="Adjuvants Adjuvants can potentially increase the immunogenicity of mucosal"/>
 <result pre="interleukin-1 beta, etc. elicit increased immune responses and protect against" exact="viral" post="challenge in poultry and other animals (Table 1). These"/>
 <result pre="Importantly, formulation of vaccines with adjuvants not only require a" exact="lower" post="amount of vaccine agents and less number of doses"/>
 <result pre="of AS03 elicited a decreased response by 3.75 mg [91]." exact="Mucosal" post="vaccination could offer an advantage in inducing local immunity"/>
 <result pre="an advantage in inducing local immunity at the site of" exact="infection" post="to systemic vaccination. However, mucosal surfaces display a broad"/>
 <result pre="in inducing local immunity at the site of infection to" exact="systemic" post="vaccination. However, mucosal surfaces display a broad tolerogenicity and"/>
 <result pre="the immunogenicity of vaccines against mucosal pathogens, including AIVs. 4.3." exact="Mucosal" post="DNA Vaccines DNA vaccines are capable of expressing immunogenic"/>
 <result pre="stability at room temperatures, and the ability to mimic natural" exact="infections" post="and elicit an appropriate immune response. Thus, DNA vaccines"/>
 <result pre="past two years, testing of DNA vaccination for targeting the" exact="mucosa" post="has revealed promising results. DNA vaccination via mucosal (oral,"/>
 <result pre="intranasal, and vaginal) routes is capable of generating mucosal and" exact="systemic" post="immunities. It has been shown that intranasal administration of"/>
 <result pre="vaccine immunogenicity by targeting the DNAs to M cells (specialized" exact="epithelial" post="cells in the mucosa). One study showed that nasal"/>
 <result pre="and Th2 effector cells in the mucous tissues [120]. 4.4." exact="Mucosal" post="Delivery Systems 4.4.1. Particulate Formulations Particulate vaccines are capable"/>
 <result pre="vaccines are capable of forming a close contact with the" exact="epithelial" post="cells in the mucosa via included anchoring devices with"/>
 <result pre="forming a close contact with the epithelial cells in the" exact="mucosa" post="via included anchoring devices with adhesive properties (lectins, specific"/>
 <result pre="microparticles, and nanoparticles including lactide-co-glycolide-based microparticles. VLPs are generated by" exact="viral" post="structural proteins alone without any genomic composition. These non-replicating"/>
 <result pre="genomic composition. These non-replicating particles are characteristic of retaining virus" exact="morphology" post="and antigenicity. Therefore, they are capable of activating innate"/>
 <result pre="antigen release and promoting antigen presentation for desired immune responses." exact="Multiple" post="studies reported that NLRP3-associated inflammasome can be activated by"/>
 <result pre="subtilis [127], Fowlpox virus [128], herpesvirus of turkey (HVT) [129]," exact="Newcastle disease" post="virus (NDV) [130] were used for AIVs defenses. For"/>
 <result pre="[127], Fowlpox virus [128], herpesvirus of turkey (HVT) [129], Newcastle" exact="disease" post="virus (NDV) [130] were used for AIVs defenses. For"/>
 <result pre="diseases. The antigen presenting system can be targeted to the" exact="mucosa" post="in which it survives and multiplies, and then carried"/>
 <result pre="proliferate in the body. As one of the most characterized" exact="viral" post="vectors, NDV has been utilized for expressing diverse influenza"/>
 <result pre="high levels of Abs against HI and protect chickens from" exact="infection" post="with H7N9 or HPAI H5N1 virus, indicative of the"/>
 <result pre="NDV-vectored influenza vaccines. Likewise, HVT has been used as a" exact="viral" post="vector for constructing avian influenza vaccines. A recombinant vector"/>
 <result pre="HVT has been used as a viral vector for constructing" exact="avian influenza" post="vaccines. A recombinant vector vaccine rHVT-H9 expressing the H9N2"/>
 <result pre="showing its potential as a universal influenza vaccine [129]. 4.5." exact="Mucosal" post="Vaccine Delivery Routes 4.5.1. Oral Vaccination Administration of mucosal"/>
 <result pre="approaches for cell-specific targeting and immunomodulation. In the mucosal tissues," exact="epithelial" post="cells are coated by a viscous fluid called mucus"/>
 <result pre="serve as the rate-limiting barrier of intestinal permeability. The mucosal" exact="epithelial" post="cells can secrete antigen-degrading enzymes. Indigenous microorganisms colonizing a"/>
 <result pre="precise quantitation of the vaccine dose required for crossing the" exact="mucosa" post="remains a significant challenge. Generally, repeated administration of higher"/>
 <result pre="the above goal, effective oral vaccines such as rotavirus and" exact="cholera" post="vaccines have been generated. However, it remains to be"/>
 <result pre="of stimulating immune responses in the nasopharynx-associated lymphoid tissue, eliciting" exact="systemic" post="and mucosal immunities in the gastric mucosa and the"/>
 <result pre="lymphoid tissue, eliciting systemic and mucosal immunities in the gastric" exact="mucosa" post="and the respiratory and/or genital tract [136]. Most soluble"/>
 <result pre="systemic and mucosal immunities in the gastric mucosa and the" exact="respiratory" post="and/or genital tract [136]. Most soluble antigens are not"/>
 <result pre="quickly eliminated via mucociliary clearance. The tight junctions of nasal" exact="epithelial" post="cells can remarkably decrease the epithelial permeability to macromolecules"/>
 <result pre="tight junctions of nasal epithelial cells can remarkably decrease the" exact="epithelial" post="permeability to macromolecules [137]. Moreover, nasal enzymes and local"/>
 <result pre="be optimized for a prolonged residence time in the nasal" exact="mucosa" post="and increased stability [134]. However, intranasal vaccination could be"/>
 <result pre="be superior to oral vaccination as the former requires markedly" exact="lower" post="doses of antigen and/or adjuvant. It has been proved"/>
 <result pre="intranasal administration of LAIVs can effectively protect from the seasonal" exact="infection" post="and even induces cross-protective immune response against drifted strains"/>
 <result pre="of antigens, inductive-site specific targeting, and adjuvant effect. 5. Protective" exact="Mucosal" post="Immunity to Newcastle Disease in Chickens: A Successful Case"/>
 <result pre="targeting, and adjuvant effect. 5. Protective Mucosal Immunity to Newcastle" exact="Disease" post="in Chickens: A Successful Case for Vaccine Design Vaccination"/>
 <result pre="mean of mucosal delivery, and nasal immunity can effectively prevent" exact="respiratory" post="diseases. At present, mucosal immunity has made great contributions"/>
 <result pre="is likely to be the most practical approach for preventing" exact="infectious diseases" post="in poultry. Immunization of Newcastle diseases has demonstrated that"/>
 <result pre="chickens. The nasal and eye-based routes were used to deliver" exact="Newcastle disease" post="attenuated vaccines. These delivery routes produce S-IgA Abs in"/>
 <result pre="The nasal and eye-based routes were used to deliver Newcastle" exact="disease" post="attenuated vaccines. These delivery routes produce S-IgA Abs in"/>
 <result pre="first week following vaccination [141]. In brief, the case of" exact="Newcastle disease" post="control demonstrates that mucosal immunization is a rapid, efficient,"/>
 <result pre="week following vaccination [141]. In brief, the case of Newcastle" exact="disease" post="control demonstrates that mucosal immunization is a rapid, efficient,"/>
 <result pre="immunization is a rapid, efficient, and economical method to prevent" exact="respiratory" post="diseases. 6. Conclusions and Perspectives Avian influenza is a"/>
 <result pre="economical method to prevent respiratory diseases. 6. Conclusions and Perspectives" exact="Avian" post="influenza is a serious respiratory disease. Although currently used"/>
 <result pre="diseases. 6. Conclusions and Perspectives Avian influenza is a serious" exact="respiratory" post="disease. Although currently used inactivated vaccines are effective, circulation"/>
 <result pre="of AIVs is accelerating, thereby increasing the risk of human" exact="infection" post="and harm to the economy and society. Therefore, speeding"/>
 <result pre="safety and reliability will have huge economic and social benefits." exact="Mucosal" post="immunity constitutes the first line of defense against AIVs;"/>
 <result pre="defense against AIVs; the mucosal delivery route elicits mucosal and" exact="systemic" post="immunities simultaneously. Compared to inactivated vaccines, mucosal vaccines stimulate"/>
 <result pre="A threat to human healthClin. Microbiol. Rev.20072024326710.1128/CMR.00037-0617428885 6.PoovorawanY.PyungpornS.PrachayangprechaS.MakkochJ.Global alert to" exact="avian influenza" post="virus infection: From H5N1 to H7N9Pathog. Glob. Health201310721722310.1179/2047773213Y.000000010323916331 7.ZhangF.BiY.WangJ.WongG.ShiW.HuF.YangY.YangL.DengX.JiangS.Human"/>
 <result pre="influenza virus infection: From H5N1 to H7N9Pathog. Glob. Health201310721722310.1179/2047773213Y.000000010323916331 7.ZhangF.BiY.WangJ.WongG.ShiW.HuF.YangY.YangL.DengX.JiangS.Human" exact="infections" post="with recently-emerging highly pathogenic H7N9 avian influenza virus in"/>
 <result pre="H7N9Pathog. Glob. Health201310721722310.1179/2047773213Y.000000010323916331 7.ZhangF.BiY.WangJ.WongG.ShiW.HuF.YangY.YangL.DengX.JiangS.Human infections with recently-emerging highly pathogenic H7N9" exact="avian influenza" post="virus in ChinaJ. Infect.201775717510.1016/j.jinf.2017.04.00128390707 8.YuanR.LiangL.WuJ.KangY.SongY.ZouL.ZhangX.NiH.KeC.Human infection with an avian"/>
 <result pre="highly pathogenic H7N9 avian influenza virus in ChinaJ. Infect.201775717510.1016/j.jinf.2017.04.00128390707 8.YuanR.LiangL.WuJ.KangY.SongY.ZouL.ZhangX.NiH.KeC.Human" exact="infection" post="with an avian influenza A/H9N2 virus in Guangdong in"/>
 <result pre="avian influenza virus in ChinaJ. Infect.201775717510.1016/j.jinf.2017.04.00128390707 8.YuanR.LiangL.WuJ.KangY.SongY.ZouL.ZhangX.NiH.KeC.Human infection with an" exact="avian influenza" post="A/H9N2 virus in Guangdong in 2016J. Infect.20177442242510.1016/j.jinf.2017.01.00328109675 9.TaubenbergerJ.K.MorensD.M.Influenza: The"/>
 <result pre="and future pandemicPublic Health Rep.2010125162610.1177/00333549101250S305 10.JiangH.WuP.UyekiT.M.HeJ.DengZ.XuW.LvQ.ZhangJ.WuY.TsangT.K.Preliminary epidemiologic assessment of human" exact="infections" post="with highly pathogenic avian influenza A(H5N6) virus, ChinaClin. Infect."/>
 <result pre="Rep.2010125162610.1177/00333549101250S305 10.JiangH.WuP.UyekiT.M.HeJ.DengZ.XuW.LvQ.ZhangJ.WuY.TsangT.K.Preliminary epidemiologic assessment of human infections with highly pathogenic" exact="avian influenza" post="A(H5N6) virus, ChinaClin. Infect. Dis.201765310.1093/cid/cix334 11.LaiS.YingQ.CowlingB.J.XiangR.WardropN.A.GilbertM.TsangT.K.PengW.FengL.HuiJ.Global epidemiology of avian"/>
 <result pre="avian influenza A(H5N6) virus, ChinaClin. Infect. Dis.201765310.1093/cid/cix334 11.LaiS.YingQ.CowlingB.J.XiangR.WardropN.A.GilbertM.TsangT.K.PengW.FengL.HuiJ.Global epidemiology of" exact="avian influenza" post="A H5N1 virus infection in humans, 1997â€&quot;2015: A systematic"/>
 <result pre="ChinaClin. Infect. Dis.201765310.1093/cid/cix334 11.LaiS.YingQ.CowlingB.J.XiangR.WardropN.A.GilbertM.TsangT.K.PengW.FengL.HuiJ.Global epidemiology of avian influenza A H5N1" exact="virus infection" post="in humans, 1997â€&quot;2015: A systematic review of individual case"/>
 <result pre="Infect. Dis.201765310.1093/cid/cix334 11.LaiS.YingQ.CowlingB.J.XiangR.WardropN.A.GilbertM.TsangT.K.PengW.FengL.HuiJ.Global epidemiology of avian influenza A H5N1 virus" exact="infection" post="in humans, 1997â€&quot;2015: A systematic review of individual case"/>
 <result pre="review of individual case dataLancet Infect. Dis.201616e108e11810.1016/S1473-3099(16)00153-527211899 12.IulianoA.D.JangY.JonesJ.DavisC.T.WentworthD.E.UyekiT.M.RoguskiK.ThompsonM.G.GubarevaL.FryA.M.Increase in Human" exact="Infections" post="with Avian Influenza A(H7N9) Virus During the Fifth Epidemic"/>
 <result pre="individual case dataLancet Infect. Dis.201616e108e11810.1016/S1473-3099(16)00153-527211899 12.IulianoA.D.JangY.JonesJ.DavisC.T.WentworthD.E.UyekiT.M.RoguskiK.ThompsonM.G.GubarevaL.FryA.M.Increase in Human Infections with" exact="Avian" post="Influenza A(H7N9) Virus During the Fifth Epidemic China, October"/>
 <result pre="Human Infections with Avian Influenza A(H7N9) Virus During the Fifth" exact="Epidemic" post="China, October 2016-February 2017Morb. Mortal. Wkly. Rep.20176625410.15585/mmwr.mm6609e228278147 13.SwayneD.E.Impact of"/>
 <result pre="control of avian influenzaAvian Dis.20125681882810.1637/10183-041012-Review.123402099 14.GiovanniC.AdelaideM.NigelT.BiancaZ.AlessandraB.EleonoraM.Mona MeherezA.AbdelA.IlariaC.Antigenic drift in H5N1" exact="avian influenza" post="virus in poultry is driven by mutations in major"/>
 <result pre="influenza virusJ. Virol.2011858718872421734057 15.SwayneD.E.KapczynskiD.Strategies and challenges for eliciting immunity against" exact="avian influenza" post="virus in birdsImmunol. Rev.201022531433110.1111/j.1600-065X.2008.00668.x18837791 16.LeeC.W.SenneD.A.SuarezD.L.Effect of vaccine use in"/>
 <result pre="of vaccine use in the evolution of Mexican lineage H5N2" exact="avian influenza" post="virusJ. Virol.2004788372838110.1128/JVI.78.15.8372-8381.200415254209 17.NeutraM.R.KozlowskiP.A.Mucosal vaccines: The promise and the challengeNat."/>
 <result pre="21.GuptaS.K.DebR.DeyS.ChellappaM.M.Toll-like receptor-based adjuvants: Enhancing the immune response to vaccines against" exact="infectious diseases" post="of chickenExpert Rev. Vaccines20141390992510.1586/14760584.2014.92023624855906 22.LundJ.M.AlexopoulouL.SatoA.KarowM.AdamsN.C.GaleN.W.IwasakiA.FlavellR.A.Recognition of single-stranded RNA viruses"/>
 <result pre="to single-stranded RNA bearing 5â€™-phosphatesScience2006314997100110.1126/science.113299817038589 24.MunirM.TRIM proteins: Another class of" exact="viral" post="victimsSci. Signal.20103jc210.1126/scisignal.3118jc220407122 25.BowieA.G.UnterholznerL.Viral evasion and subversion of pattern-recognition receptor"/>
 <result pre="29.FranchiL.EigenbrodT.Munoz-PlanilloR.NunezG.The inflammasome: A caspase-1-activation platform that regulates immune responses and" exact="disease" post="pathogenesisNat. Immunol.20091024124710.1038/ni.170319221555 30.PhilpottD.J.SorbaraM.T.RobertsonS.J.CroitoruK.GirardinS.E.NOD proteins: Regulators of inflammation in health"/>
 <result pre="vivo innate immunity to influenza A virus through recognition of" exact="viral" post="RNAImmunity20093055656510.1016/j.immuni.2009.02.00519362020 35.ThomasP.G.DashP.AldridgeJ.R.Jr.EllebedyA.H.ReynoldsC.FunkA.J.MartinW.J.LamkanfiM.WebbyR.J.BoydK.L.et al.The intracellular sensor NLRP3 mediates key innate"/>
 <result pre="regulation of caspase-1Immunity20093056657510.1016/j.immuni.2009.02.00619362023 36.KrammerF.The human antibody response to influenza A" exact="virus infection" post="and vaccinationNat. Rev. Immunol.20191938339710.1038/s41577-019-0143-630837674 37.Van de SandtC.E.KreijtzJ.H.RimmelzwaanG.F.Evasion of influenza"/>
 <result pre="of caspase-1Immunity20093056657510.1016/j.immuni.2009.02.00619362023 36.KrammerF.The human antibody response to influenza A virus" exact="infection" post="and vaccinationNat. Rev. Immunol.20191938339710.1038/s41577-019-0143-630837674 37.Van de SandtC.E.KreijtzJ.H.RimmelzwaanG.F.Evasion of influenza"/>
 <result pre="and adaptive immune responsesViruses201241438147610.3390/v409143823170167 38.SchulmanJ.L.KhakpourM.KilbourneE.D.Protective effects of specific immunity to" exact="viral" post="neuraminidase on influenza virus infection of miceJ. Virol.1968277878610.1128/JVI.2.8.778-786.19685701819 39.LaMereM.W.LamH.T.MoquinA.HaynesL.LundF.E.RandallT.D.KaminskiD.A.Contributions"/>
 <result pre="38.SchulmanJ.L.KhakpourM.KilbourneE.D.Protective effects of specific immunity to viral neuraminidase on influenza" exact="virus infection" post="of miceJ. Virol.1968277878610.1128/JVI.2.8.778-786.19685701819 39.LaMereM.W.LamH.T.MoquinA.HaynesL.LundF.E.RandallT.D.KaminskiD.A.Contributions of antinucleoprotein IgG to heterosubtypic"/>
 <result pre="effects of specific immunity to viral neuraminidase on influenza virus" exact="infection" post="of miceJ. Virol.1968277878610.1128/JVI.2.8.778-786.19685701819 39.LaMereM.W.LamH.T.MoquinA.HaynesL.LundF.E.RandallT.D.KaminskiD.A.Contributions of antinucleoprotein IgG to heterosubtypic"/>
 <result pre="heterosubtypic immunity against influenza virusJ. Immunol.20111864331433910.4049/jimmunol.100305721357542 40.VandervenH.A.Ana-Sosa-BatizF.JegaskandaS.RockmanS.LaurieK.BarrI.ChenW.WinesB.HogarthP.M.LambeT.et al.What Lies Beneath:" exact="Antibody" post="Dependent Natural Killer Cell Activation by Antibodies to Internal"/>
 <result pre="Exp. Med.19971852133214110.1084/jem.185.12.21339182685 42.LukensM.V.KruijsenD.CoenjaertsF.E.KimpenJ.L.van BleekG.M.Respiratory syncytial virus-induced activation and migration of" exact="respiratory" post="dendritic cells and subsequent antigen presentation in the lung-draining"/>
 <result pre="lung-draining lymph nodeJ. Virol.2009837235724310.1128/JVI.00452-0919420085 43.PapeK.A.KhorutsA.MondinoA.JenkinsM.K.Inflammatory cytokines enhance the in vivo" exact="clonal" post="expansion and differentiation of antigen-activated CD4+ T cellsJ. Immunol.19971595915989218573"/>
 <result pre="Tissue-retentive lung memory CD4 T cells mediate optimal protection to" exact="respiratory" post="virus infectionJ. Immunol.20111875510551410.4049/jimmunol.110224322058417 49.BrownD.M.DilzerA.M.MeentsD.L.SwainS.L.CD4 T cell-mediated protection from lethal"/>
 <result pre="efficiently transport influenza virus to the lymph node and load" exact="viral" post="antigen onto MHC class I for presentation to CD8"/>
 <result pre="anti-hemagglutinin IgA and IgG antibodies in different sites of the" exact="respiratory" post="tract of vaccinated mice in preventing lethal influenza pneumoniaVaccine2003212362237110.1016/S0264-410X(03)00078-112744867"/>
 <result pre="immunity and memory at mucosal surfacesVaccine20072554675484410.1016/j.vaccine.2006.12.00117227687 62.TamuraS.FunatoH.HirabayashiY.SuzukiY.NagamineT.AizawaC.KurataT.Cross-protection against influenza A" exact="virus infection" post="by passively transferred respiratory tract IgA antibodies to different"/>
 <result pre="and memory at mucosal surfacesVaccine20072554675484410.1016/j.vaccine.2006.12.00117227687 62.TamuraS.FunatoH.HirabayashiY.SuzukiY.NagamineT.AizawaC.KurataT.Cross-protection against influenza A virus" exact="infection" post="by passively transferred respiratory tract IgA antibodies to different"/>
 <result pre="surfacesVaccine20072554675484410.1016/j.vaccine.2006.12.00117227687 62.TamuraS.FunatoH.HirabayashiY.SuzukiY.NagamineT.AizawaC.KurataT.Cross-protection against influenza A virus infection by passively transferred" exact="respiratory" post="tract IgA antibodies to different hemagglutinin moleculesEur. J. Immunol.1991211337134410.1002/eji.18302106021646112"/>
 <result pre="influenza epidemicsExpert. Rev. Vaccines20181768769610.1080/14760584.2018.150774330092690 64.Asahi-OzakiY.YoshikawaT.IwakuraY.SuzukiY.TamuraS.KurataT.SataT.Secretory IgA antibodies provide cross-protection against" exact="infection" post="with different strains of influenza B virusJ. Med. Virol.20047432833510.1002/jmv.2017315332283"/>
 <result pre="Acad. Sci.201212479711610.1111/j.1749-6632.2011.06378.x22260403 67.Van GinkelF.W.NguyenH.H.McGheeJ.R.Vaccines for mucosal immunity to combat emerging" exact="infectious" post="diseasesEmerg. Infect. Dis.2000612313210.3201/eid0602.00020410756145 68.SpaldingD.M.WilliamsonS.I.KoopmanW.J.McGheeJ.R.Preferential induction of polyclonal IgA secretion"/>
 <result pre="Formulation and production strategiesEur. J. Pharm. Biopharm.20159425126310.1016/j.ejpb.2015.05.02326047796 71.VincentA.L.Ciacci-ZanellaJ.R.LorussoA.GaugerP.C.ZanellaE.L.KehrliM.E.K.Jr.JankeB.H.LagerK.M.Efficacy of inactivated" exact="swine influenza" post="virus vaccines against the 2009 A/H1N1 influenza virus in"/>
 <result pre="neutralising mucosal IgA antibodies in humansVaccine2014321897190010.1016/j.vaccine.2014.02.00924560674 74.RossK.F.HerzbergM.C.Autonomous immunity in mucosal" exact="epithelial" post="cells: Fortifying the barrier against infectionMicrobes. Infect.20161838739810.1016/j.micinf.2016.03.00827005450 75.TamuraS.TanimotoT.KurataT.Mechanisms of"/>
 <result pre="against infectionMicrobes. Infect.20161838739810.1016/j.micinf.2016.03.00827005450 75.TamuraS.TanimotoT.KurataT.Mechanisms of broad cross-protection provided by influenza" exact="virus infection" post="and their application to vaccinesJpn. J. Infect. Dis.20055819520716116250 76.HasegawaH.IchinoheT.AinaiA.TamuraS.KurataT.Development"/>
 <result pre="infectionMicrobes. Infect.20161838739810.1016/j.micinf.2016.03.00827005450 75.TamuraS.TanimotoT.KurataT.Mechanisms of broad cross-protection provided by influenza virus" exact="infection" post="and their application to vaccinesJpn. J. Infect. Dis.20055819520716116250 76.HasegawaH.IchinoheT.AinaiA.TamuraS.KurataT.Development"/>
 <result pre="H5N1 influenza virusesTher. Clin. Risk. Manag.2009512513210.2147/TCRM.S329719436601 77.TamuraS.YamanakaA.ShimoharaM.TomitaT.KomaseK.TsudaY.SuzukiY.NagamineT.KawaharaK.DanbaraH.et al.Synergistic action of" exact="cholera" post="toxin B subunit (and Escherichia coli heat-labile toxin B"/>
 <result pre="coli heat-labile toxin B subunit) and a trace amount of" exact="cholera" post="whole toxin as an adjuvant for nasal influenza vaccineVaccine19941241942610.1016/0264-410X(94)90118-X8023550"/>
 <result pre="and long-term protective efficacy against clade 2.3.4.4 H5N2 highly pathogenic" exact="avian influenza" post="virus following prime-boost vaccination in turkeysVaccine2017355637564310.1016/j.vaccine.2017.08.05928886943 85.SlepushkinA.N.DukovaV.S.KalegaevaV.A.KaganA.N.TemriukE.E.Results of studying"/>
 <result pre="86.RudenkoL.YeolekarL.KiselevaI.IsakovasivakI.Development and approval of live attenuated influenza vaccines based on" exact="Russian" post="master donor viruses: Process challenges and success storiesVaccine2016345436544110.1016/j.vaccine.2016.08.01827593158 87.RudenkoL.KiselevaI.KrutikovaE.StepanovaE.RekstinA.DoninaS.PisarevaM.GrigorievaE.KryshenK.MuzhikyanA.et"/>
 <result pre="in the Salmonella pathogenicity island 2, as a live, oral" exact="typhoid" post="vaccine in human volunteersVaccine20062411612310.1016/j.vaccine.2005.08.00816140433 90.JohnS.LowenA.C.LindomarP.MatthewA.AliciaS.RandyA.PerezD.R.AdolfoG.S.PeterP.Live attenuated influenza viruses containing"/>
 <result pre="heterologous H5N1 influenza booster vaccination 6 or 18 months after" exact="primary" post="vaccination in adults: A randomized controlled clinical trialVaccine20153355956710.1016/j.vaccine.2014.11.01825448092 92.NicolaP.SusannaE.Adjuvanted"/>
 <result pre="immunization in chickenPoult. Sci.2013922651266010.3382/ps.2013-0319324046412 94.ChaungH.C.ChengL.T.HungL.H.TsaiP.C.SkountzouI.WangB.CompansR.W.LienY.Y.Salmonella flagellin enhances mucosal immunity of" exact="avian influenza" post="vaccine in chickensVet. Microbiol.2012157697710.1016/j.vetmic.2011.12.01422226542 95.PatelB.A.GomisS.DarA.WillsonP.J.BabiukL.A.PotterA.MutwiriG.TikooS.K.Oligodeoxynucleotides containing CpG motifs (CpG-ODN)"/>
 <result pre="containing CpG motifs (CpG-ODN) predominantly induce Th1-type immune response in" exact="neonatal" post="chicksDev. Comp. Immunol.2008321041104910.1016/j.dci.2008.02.00718395255 96.St PaulM.BrisbinJ.T.Abdul-CareemM.F.SharifS.Immunostimulatory properties of Toll-like receptor"/>
 <result pre="Toll-like receptor ligands in chickensVet. Immunol. Immunopathol.201315219119910.1016/j.vetimm.2012.10.01323305711 97.GirardF.PeryP.NaciriM.QuereP.Adjuvant effect of" exact="cholera" post="toxin on systemic and mucosal immune responses in chickens"/>
 <result pre="in chickensVet. Immunol. Immunopathol.201315219119910.1016/j.vetimm.2012.10.01323305711 97.GirardF.PeryP.NaciriM.QuereP.Adjuvant effect of cholera toxin on" exact="systemic" post="and mucosal immune responses in chickens infected with E."/>
 <result pre="with the recombinant proteins flagellin and the subunit B of" exact="cholera" post="toxin associated with Lactobacillus spp.Poult. Sci.201493394510.3382/ps.2013-0337224570421 99.LeiH.ShengZ.DingQ.ChenJ.WeiX.LamD.M.XuY.Evaluation of oral"/>
 <result pre="with Lactobacillus spp.Poult. Sci.201493394510.3382/ps.2013-0337224570421 99.LeiH.ShengZ.DingQ.ChenJ.WeiX.LamD.M.XuY.Evaluation of oral immunization with recombinant" exact="avian influenza" post="virus HA1 displayed on the Lactococcus lactis surface and"/>
 <result pre="the Lactococcus lactis surface and combined with the mucosal adjuvant" exact="cholera" post="toxin subunit BClin. Vaccine Immunol.2011181046105110.1128/CVI.00050-1121632890 100.LalsiamtharaJ.LeeJ.H.Immunization with Salmonella Enteritidis"/>
 <result pre="BClin. Vaccine Immunol.2011181046105110.1128/CVI.00050-1121632890 100.LalsiamtharaJ.LeeJ.H.Immunization with Salmonella Enteritidis secreting mucosal adjuvant" exact="labile" post="toxin confers protection against wild type challenge via augmentation"/>
 <result pre="PaulM.MallickA.I.ReadL.R.VillanuevaA.I.ParviziP.Abdul-CareemM.F.NagyE.SharifS.Prophylactic treatment with Toll-like receptor ligands enhances host immunity to" exact="avian influenza" post="virus in chickensVaccine2012304524453110.1016/j.vaccine.2012.04.03322531557 103.ScheepersK.BechtH.Protection of mice against an influenza"/>
 <result pre="influenza virus in chickensVaccine2012304524453110.1016/j.vaccine.2012.04.03322531557 103.ScheepersK.BechtH.Protection of mice against an influenza" exact="virus infection" post="by oral vaccination with viral nucleoprotein incorporated into immunostimulating"/>
 <result pre="virus in chickensVaccine2012304524453110.1016/j.vaccine.2012.04.03322531557 103.ScheepersK.BechtH.Protection of mice against an influenza virus" exact="infection" post="by oral vaccination with viral nucleoprotein incorporated into immunostimulating"/>
 <result pre="mice against an influenza virus infection by oral vaccination with" exact="viral" post="nucleoprotein incorporated into immunostimulating complexesMed. Microbiol. Immunol.199418326527810.1007/BF001984607715538 104.RenZ.ZhaoY.LiuJ.JiX.MengL.WangT.SunW.ZhangK.SangX.YuZ.et al.Inclusion"/>
 <result pre="following intramuscular and oral immunization of miceVaccine2018365990599810.1016/j.vaccine.2018.08.05330172635 105.WangY.ShanC.MingS.LiuY.DuY.JiangG.Immunoadjuvant effects of" exact="bacterial" post="genomic DNA and CpG oligodeoxynucleotides on avian influenza virus"/>
 <result pre="105.WangY.ShanC.MingS.LiuY.DuY.JiangG.Immunoadjuvant effects of bacterial genomic DNA and CpG oligodeoxynucleotides on" exact="avian influenza" post="virus subtype H5N1 inactivated oil emulsion vaccine in chickenRes."/>
 <result pre="plasmids with multiple copies of a CpG motif coadministrated with" exact="avian influenza" post="vaccine in chickensVaccine2011294668467510.1016/j.vaccine.2011.04.10421557981 107.TateishiK.FujihashiK.YamamotoN.HasegawaH.AinaiA.SatoK.IhoS.YamamotoS.MaeyamaJ.I.OdagiriT.et al.CpG ODN G9.1 as a"/>
 <result pre="al.CpG ODN G9.1 as a novel nasal ODN adjuvant elicits" exact="complete" post="protection from influenza virus infection without causing inflammatory immune"/>
 <result pre="a novel nasal ODN adjuvant elicits complete protection from influenza" exact="virus infection" post="without causing inflammatory immune responsesVaccine2019375382538910.1016/j.vaccine.2019.07.03231345642 108.KangH.WangH.YuQ.YangQ.A novel combined adjuvant"/>
 <result pre="novel nasal ODN adjuvant elicits complete protection from influenza virus" exact="infection" post="without causing inflammatory immune responsesVaccine2019375382538910.1016/j.vaccine.2019.07.03231345642 108.KangH.WangH.YuQ.YangQ.A novel combined adjuvant"/>
 <result pre="immune responsesVaccine2019375382538910.1016/j.vaccine.2019.07.03231345642 108.KangH.WangH.YuQ.YangQ.A novel combined adjuvant strongly enhances mucosal and" exact="systemic" post="immunity to low pathogenic avian influenza after oral immunization"/>
 <result pre="adjuvant strongly enhances mucosal and systemic immunity to low pathogenic" exact="avian influenza" post="after oral immunization in ducksPoult. Sci.2013921543155110.3382/ps.2012-0300023687150 109.SerradellM.C.RupilL.L.MartinoR.A.PruccaC.G.CarranzaP.G.SauraA.FernandezE.A.GargantiniP.R.TenagliaA.H.PetitiJ.P.et al.Efficient oral"/>
 <result pre="proteinsNat. Commun.20191036110.1038/s41467-018-08265-930664644 110.OnuigboE.IseghohimhenJ.ChahK.GyangM.AttamaA.Chitosan/alginate microparticles for the oral delivery of fowl" exact="typhoid" post="vaccine: Innate and acquired immunityVaccine2018364973497810.1016/j.vaccine.2018.05.08730017142 111.SvindlandS.C.Jul-LarsenA.PathiranaR.AndersenS.MadhunA.MontomoliE.Jabbal-GillI.CoxR.J.The mucosal and systemic"/>
 <result pre="for the oral delivery of fowl typhoid vaccine: Innate and" exact="acquired" post="immunityVaccine2018364973497810.1016/j.vaccine.2018.05.08730017142 111.SvindlandS.C.Jul-LarsenA.PathiranaR.AndersenS.MadhunA.MontomoliE.Jabbal-GillI.CoxR.J.The mucosal and systemic immune responses elicited by"/>
 <result pre="fowl typhoid vaccine: Innate and acquired immunityVaccine2018364973497810.1016/j.vaccine.2018.05.08730017142 111.SvindlandS.C.Jul-LarsenA.PathiranaR.AndersenS.MadhunA.MontomoliE.Jabbal-GillI.CoxR.J.The mucosal and" exact="systemic" post="immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1"/>
 <result pre="lymphopoietinNat. Immunol.20192059360110.1038/s41590-019-0345-x30886417 115.KimotoT.KimH.SakaiS.TakahashiE.KidoH.Oral vaccination with influenza hemagglutinin combined with human" exact="pulmonary" post="surfactant-mimicking synthetic adjuvant SF-10 induces efficient local and systemic"/>
 <result pre="human pulmonary surfactant-mimicking synthetic adjuvant SF-10 induces efficient local and" exact="systemic" post="immunity compared with nasal and subcutaneous vaccination and provides"/>
 <result pre="H9 hemagglutinins and N1 neuraminidase elicit protective immunity to heterologous" exact="avian influenza" post="viruses in chickensVirology201750117618210.1016/j.virol.2016.12.00127936463 124.ZhuM.WangR.NieG.Applications of nanomaterials as vaccine adjuvantsHum."/>
 <result pre="approach on the development of a mucosal vaccine against strangles:" exact="Systemic" post="and mucosal immune responses in a mouse modelVaccine2009271230124110.1016/j.vaccine.2008.12.00419114079 126.ChiouC.J.TsengL.P.DengM.C.JiangP.R.TasiS.L.ChungT.W.HuangY.Y.LiuD.Z.Mucoadhesive"/>
 <result pre="a mouse modelVaccine2009271230124110.1016/j.vaccine.2008.12.00419114079 126.ChiouC.J.TsengL.P.DengM.C.JiangP.R.TasiS.L.ChungT.W.HuangY.Y.LiuD.Z.Mucoadhesive liposomes for intranasal immunization with an" exact="avian influenza" post="virus vaccine in chickensBiomaterials2009305862586810.1016/j.biomaterials.2009.06.04619608270 127.SongM.HongH.A.HuangJ.M.ColenuttC.KhangD.D.NguyenT.V.A.ParkS.M.ShimB.S.SongH.H.CheonI.S.Killed Bacillus subtilis spores as"/>
 <result pre="for an H5N1 vaccineVaccine2012303266327710.1016/j.vaccine.2012.03.01622446640 128.EricN.OlivierG.MichelA.VÃ©roniqueJ.Prime-boost vaccination with recombinant H5-fowlpox and" exact="Newcastle disease" post="virus vectors affords lasting protection in SPF Muscovy ducks"/>
 <result pre="an H5N1 vaccineVaccine2012303266327710.1016/j.vaccine.2012.03.01622446640 128.EricN.OlivierG.MichelA.VÃ©roniqueJ.Prime-boost vaccination with recombinant H5-fowlpox and Newcastle" exact="disease" post="virus vectors affords lasting protection in SPF Muscovy ducks"/>
 <result pre="expressing H9 hemagglutinin providing protection against H9N2 avian influenzaVirology201952971510.1016/j.virol.2019.01.00430641481 130.KimS.H.PalduraiA.XiaoS.CollinsP.L.SamalS.K.Modified" exact="Newcastle disease" post="virus vectors expressing the H5 hemagglutinin induce enhanced protection"/>
 <result pre="H9 hemagglutinin providing protection against H9N2 avian influenzaVirology201952971510.1016/j.virol.2019.01.00430641481 130.KimS.H.PalduraiA.XiaoS.CollinsP.L.SamalS.K.Modified Newcastle" exact="disease" post="virus vectors expressing the H5 hemagglutinin induce enhanced protection"/>
 <result pre="the H5 hemagglutinin induce enhanced protection against highly pathogenic H5N1" exact="avian influenza" post="virus in chickensVaccine2014324428443510.1016/j.vaccine.2014.06.06124968158 131.ChoY.LamichhaneB.NagyA.ChowdhuryI.R.SamalS.K.KimS.H.Co-expression of the Hemagglutinin and Neuraminidase"/>
 <result pre="chickensVaccine2014324428443510.1016/j.vaccine.2014.06.06124968158 131.ChoY.LamichhaneB.NagyA.ChowdhuryI.R.SamalS.K.KimS.H.Co-expression of the Hemagglutinin and Neuraminidase by Heterologous Newcastle" exact="Disease" post="Virus Vectors Protected Chickens against H5 Clade 2.3.4.4 HPAI"/>
 <result pre="Protected Chickens against H5 Clade 2.3.4.4 HPAI VirusesSci. Rep.201881685410.1038/s41598-018-35337-z30443041 132.HuZ.LiuX.JiaoX.LiuX.Newcastle" exact="disease" post="virus (NDV) recombinant expressing the hemagglutinin of H7N9 avian"/>
 <result pre="132.HuZ.LiuX.JiaoX.LiuX.Newcastle disease virus (NDV) recombinant expressing the hemagglutinin of H7N9" exact="avian influenza" post="virus protects chickens against NDV and highly pathogenic avian"/>
 <result pre="avian influenza virus protects chickens against NDV and highly pathogenic" exact="avian influenza" post="A (H7N9) virus challengesVaccine201735658510.1016/j.vaccine.2017.10.01029042201 133.MacdonaldT.T.The mucosal immune systemParasite Immunol.20032523524610.1046/j.1365-3024.2003.00632.x12969442"/>
 <result pre="of oral vaccines in developing countries: Lessons from a live" exact="cholera" post="vaccineBMC Biol.2010812910.1186/1741-7007-8-12920920375 136.PerB.Potential of nasopharynx-associated lymphoid tissue for vaccine"/>
 <result pre="one-day-old SPF and conventional layer chicks with two different live" exact="Newcastle disease" post="vaccinesVaccine2009273631364210.1016/j.vaccine.2009.03.06819464544 Figure 1 The innate and adaptive immunity against"/>
 <result pre="SPF and conventional layer chicks with two different live Newcastle" exact="disease" post="vaccinesVaccine2009273631364210.1016/j.vaccine.2009.03.06819464544 Figure 1 The innate and adaptive immunity against"/>
 <result pre="Route Immune Responses Enterotoxins Cholera toxin GM1 Nasal or oral" exact="Increased" post="specific IgA and IgG [97] the subunit B of"/>
 <result pre="Increased specific IgA and IgG [97] the subunit B of" exact="cholera" post="toxin GM1 Nasal or oral Increased specific IgA, IgG"/>
 <result pre="the subunit B of cholera toxin GM1 Nasal or oral" exact="Increased" post="specific IgA, IgG and T cell response [98,99] Mutant"/>
 <result pre="coli heat-labile enterotoxin GM1 and other gangliosides Nasal or oral" exact="Increased" post="S-IgA, IgG and T cell response, enhanced IFN-Î³, IL-6"/>
 <result pre="and cloacal virus shedding [102,103] Flagellin TLR5 Nasal or oral" exact="Increased" post="IgY and IgA, protection of lethal viral challenge [94,104]"/>
 <result pre="Nasal or oral Increased IgY and IgA, protection of lethal" exact="viral" post="challenge [94,104] CpG TLR9/TL21 Nasal or oral Increased S-IgA,"/>
 <result pre="of lethal viral challenge [94,104] CpG TLR9/TL21 Nasal or oral" exact="Increased" post="S-IgA, IgG and IFN-Î³ [105,106,107,108] Variant-specific surface proteins TLR4"/>
 <result pre="S-IgA, IgG and IFN-Î³ [105,106,107,108] Variant-specific surface proteins TLR4 Oral" exact="Increased" post="IgA, IgG and IFN-Î³, protection of viral challenge [109]"/>
 <result pre="proteins TLR4 Oral Increased IgA, IgG and IFN-Î³, protection of" exact="viral" post="challenge [109] Mucoadhesives Chitosan Tight junctions Nasal or oral"/>
 <result pre="viral challenge [109] Mucoadhesives Chitosan Tight junctions Nasal or oral" exact="Increased" post="IgG and IFN-Î³, 100% protection for fowl typhoid [110,111]"/>
 <result pre="or oral Increased IgG and IFN-Î³, 100% protection for fowl" exact="typhoid" post="[110,111] Lectins M cells Nasal IgG and IgA induction,"/>
 <result pre="induced heterosubtypic immunity [112] Cytokines chicken interleukin-1 beta IL-1R Nasal" exact="Increased" post="specific IgA, S-IgA and IFN-Î³ [113] IFN-Î» M cells"/>
 <result pre="IFN-Î» M cells Nasal IgG1 and IgA induction, protection of" exact="viral" post="challenge [114] Synthetic adjuvant SF-10 Dendritic cells Oral Increased"/>
 <result pre="of viral challenge [114] Synthetic adjuvant SF-10 Dendritic cells Oral" exact="Increased" post="specific IgA, S-IgA, IgG and cytokine production [115]"/>
</results>
